News

G2 Goldfields Inc.: G2 Continues to Expand New Surface Gold Discovery and Provides Exploration Update
G2 drills 41m @ 1.2 g/t Au & 50m @ 1.1 g/t Au and continues to expand significant new gold discoveryRegional soil sampling ...
Q2 Metals Corp: Q2 Metals Extends Mineralized Zone Strike Length to 1.5 Kilometres and Concludes the 2025 Winter Program at the
Winter Program concluded with 6,997 metres (m) drilled across 14 holes.Drill hole CS25-028 encountered eight (8) spodumene ...
Easterly Government Properties Completes Reverse Stock Split
Easterly Government Properties, Inc. (NYSE: DEA) (the "Company" or "Easterly"), a fully integrated real estate investment trust focused primarily on the acquisition, development ...
Marvion Inc. Announces Annual Financial Results for 2024 with 134% Gain in Year-to-Year Revenue
Marvion Inc. (OTC: MNVC) filed and reported the financial results with the period ended 31 December, 2025. For annual ...
Bright Scholar Education Holdings Ltd.: Bright Scholar Announces Unaudited Financial Results for the Second Quarter of Fiscal Year 2025
Net income from continuing operations increased 223.6% YoY to GBP3.2 million Management to hold a conference call today at 7:00 a.m. Eastern Time CAMBRIDGE, England ...
Potomac Bancshares, Inc.: Potomac Bancshares Reports 30% Increase In 2025 First Quarter Earnings Over Prior Year
Potomac Bancshares, Inc. (the "Company") (OTCPK: PTBS), the bank holding company of Bank of Charles Town (the "Bank" or "BCT"), ...
Portage Biotech Inc.: Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a ...
Regeneron Pharmaceuticals, Inc.: Lynozyfic (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...
InMode Ltd.: InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease
Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") ...
Opera Limited: Opera Reports 40% Revenue Growth in the First Quarter 2025, Raises Full-Year Guidance Ranges for Both Revenue and Adjusted EBITDA
Revenue accelerated further to 40% year-over-year growth and $142.7 million in the quarter, far exceeding the guidance range Adjusted EBITDA of $32.3 million, a 23% ...
ADMA Biologics, Inc.: ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process ...
High Tide Inc.: High Tide Reports Approximately $6.8 Million in Retail Sales During '4/20' Long Weekend
The Company Also Completed its Annual 4/20 Giveaway CALGARY, AB, April 28, 2025 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: ...